Biotech & Healthcare EquitiesBiotech Binary Catalysts Cluster 2026-2027: OCU410 Shows 31% Lesion Reduction, SIL204 Enters Phase 2/3 for Pancreatic CancerSalvado•Mar 26, 2026
Biotech EquitiesREGENXBIO's RGX-202 Could Be a Major RGNX Catalyst: What Investors Need to Know About the 2027 DMD LaunchViaNews Editorial Team (Markets)•Feb 18, 2026
